Vena, A.; Traman, L.; Bavastro, M.; Limongelli, A.; Dentone, C.; Magnè, F.; Giacobbe, D.R.; Mikulska, M.; Taramasso, L.; Di Biagio, A.;
et al. Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. Vaccines 2022, 10, 1141.
https://doi.org/10.3390/vaccines10071141
AMA Style
Vena A, Traman L, Bavastro M, Limongelli A, Dentone C, Magnè F, Giacobbe DR, Mikulska M, Taramasso L, Di Biagio A,
et al. Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. Vaccines. 2022; 10(7):1141.
https://doi.org/10.3390/vaccines10071141
Chicago/Turabian Style
Vena, Antonio, Luca Traman, Martina Bavastro, Alessandro Limongelli, Chiara Dentone, Federica Magnè, Daniele Roberto Giacobbe, Malgorzata Mikulska, Lucia Taramasso, Antonio Di Biagio,
and et al. 2022. "Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression" Vaccines 10, no. 7: 1141.
https://doi.org/10.3390/vaccines10071141
APA Style
Vena, A., Traman, L., Bavastro, M., Limongelli, A., Dentone, C., Magnè, F., Giacobbe, D. R., Mikulska, M., Taramasso, L., Di Biagio, A., & Bassetti, M.
(2022). Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. Vaccines, 10(7), 1141.
https://doi.org/10.3390/vaccines10071141
